Additional Capital Investment Plan for the Shinagawa CPF
First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「As the plan is being reviewed, the scheduled completion date for Shinagawa CPF has not been determined.」
The Shinagawa CPF equipment plan remains at ¥2,690 million in total, with ¥1,855 million already paid, while the scheduled completion date remains undetermined. - FY2021-Q3SoftenedAnnual report
「Because demand for contract manufacturing was below initial expectations, capacity expansion at the cell culture and processing facility was no longer necessary during the period originally scheduled for the expenditure. The expenditure schedule is therefore being changed due to the review of the capital investment timing and other factors.」
Because demand for contract manufacturing was below expectations, the timing of the capacity expansion investment at the cell culture and processing facility was reviewed, extending the planned expenditure period to September 2024. - FY2019SoftenedAnnual report
「As the plan is being reviewed, the scheduled completion date for the Shinagawa CPF cell culture and processing facility for regenerative and cell medicine has not been determined.」
The Shinagawa CPF equipment plan totals ¥2,690 million, of which ¥1,855 million has already been paid, while the scheduled completion date became undetermined due to the plan review. - FY2017RestatedAnnual report
「Shinagawa CPF (Shinagawa-ku, Tokyo); cell-processing business; cell culture and processing facility for regenerative and cellular medicine; planned investment ¥2,590 million; amount paid to date ¥1,538 million; funding from equity financing and internal funds; construction started January 2014; scheduled completion September 2020.」
The Company disclosed a capital expenditure plan for Shinagawa CPF totaling ¥2,590 million, of which ¥1,538 million had been paid, with completion scheduled for September 2020.